ILMN - Illumina, Inc.
| Previous close | 310.55 |
| Open | 311.26 |
| Bid | 309.61 x 900 |
| Ask | 309.70 x 900 |
| Day's range | 307.17 - 312.45 |
| 52-week range | 263.30 - 380.76 |
| Volume | 474,615 |
| Avg. volume | 1,010,975 |
| Market cap | 45.488B |
| Beta (3Y monthly) | 1.31 |
| PE ratio (TTM) | 49.13 |
| EPS (TTM) | 6.30 |
| Earnings date | 24 Oct 2019 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 329.25 |
- Zacks
Analysts Estimate Illumina (ILMN) to Report a Decline in Earnings: What to Look Out for
Illumina (ILMN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks
Can Sequencing Products Drive Illumina's (ILMN) Q3 Earnings?
Illumina (ILMN) is taking a cautious approach after a disappointing second quarter.
- Zacks
QIAGEN Inks Deal With Illumina to Deliver NGS-Based IVD Kits
QIAGEN (QGEN) aims to fast-track the adoption of NGS-based IVD test and improve patient outcomes through the new partnership deal.
- Zacks
Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits
Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.
- Business Wire
Illumina to Announce Third Quarter 2019 Financial Results on Thursday, October 24, 2019
Illumina, Inc. (ILMN) today announced that it will issue results for third quarter 2019 following the close of market on Thursday, October 24, 2019. On the same day, at 2:00 pm Pacific Time (5:00 pm Eastern Time) Francis deSouza, President and Chief Executive Officer, and Sam Samad, Senior Vice President and Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. The conference call will begin at 2:00 pm Pacific Time (5:00 pm Eastern Time) on Thursday, October 24, 2019.
- Business Wire
QIAGEN and Illumina Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
Partnership to accelerate the adoption of next-generation sequencing in clinical decision-making
- Business Wire
Illumina and QIAGEN Partner to Deliver Sequencing-Based In-Vitro Diagnostic (IVD) Tests
Illumina, Inc. (ILMN) and QIAGEN N.V. (QGEN) (Frankfurt Prime Standard: QIA) today announced a 15-year partnership intended to broaden the availability and use of NGS-based IVD kits, including companion diagnostics, for patient management. The agreement grants QIAGEN non-exclusive rights to develop and globally commercialize IVD kits to be used together with Illumina’s MiSeq™ Dx and NextSeq™ 550Dx Systems. The agreement also includes rights for expansion of the partnership on future Illumina diagnostic (Dx) systems.
- Simply Wall St.
Does Illumina (NASDAQ:ILMN) Deserve A Spot On Your Watchlist?
Some have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of...
- Zacks
Illumina, Broad Institute Partner on Secondary Genomic Analysis
The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.
- Zacks
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Business Wire
Illumina and Broad Institute Announce Agreement to Co-Develop Genomic Secondary Analysis Tools
Illumina, Inc. (ILMN) and the Broad Institute of MIT and Harvard today announced they have entered into a collaboration for the co-development of secondary genomic analysis algorithms and software. Top data scientists from both institutions will collaborate to bring together the industry-leading open-source GATK algorithms with the speed and enhanced accuracy of Illumina’s DRAGEN™ (Dynamic Read Analysis for GENomics) Bio-IT Platform for commonly used methods, including small variant (SNV) and large variant (CNV/SV) detection.
- Zacks
Illumina (ILMN) Outpaces Stock Market Gains: What You Should Know
Illumina (ILMN) closed at $300.15 in the latest trading session, marking a +1.65% move from the prior day.
- Zacks
Illumina (ILMN) Inks Deal to Develop Distributable Test Kits
Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.
- Zacks
Illumina (ILMN) Gains on Product Pipeline, Global Footprint
Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).
- Zacks
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
The Zacks Analyst Blog Highlights: Target, Illumina, T-Mobile US, Xcel and Regeneron
- Business Wire
Illumina Names Joydeep Goswami Senior Vice President of Corporate Development and Strategic Planning
Illumina, Inc. (ILMN) today announced the appointment of Joydeep Goswami as Senior Vice President of Corporate Development and Strategic Planning. Mr. Goswami will be responsible for driving planning, strategic partnerships and acquisitions, and will report to President and Chief Executive Officer, Francis deSouza. With more than 20 years of global experience, Mr. Goswami has a strong track record of developing strategy and leading new product development, partnerships, licensing, and mergers and acquisitions.
- Zacks
Top Research Reports for Target, Illumina & T-Mobile US
Top Research Reports for Target, Illumina & T-Mobile US
- Zacks
Illumina (ILMN) Stock Moves 0.72%: What You Should Know
In the latest trading session, Illumina (ILMN) closed at $305.20, marking a +0.72% move from the previous day.
- Zacks
Illumina (ILMN) Gains As Market Dips: What You Should Know
Illumina (ILMN) closed the most recent trading day at $300.91, moving +1.14% from the previous trading session.
- Business Wire
Illumina Recommends Stockholders Reject Mini-Tender Offer by TRC Capital Corporation
Illumina, Inc. (“Illumina”) (ILMN) has been notified of an unsolicited “mini-tender offer” by TRC Capital Corporation (“TRC”) to purchase up to 500,000 shares of Illumina common stock at a price of $268.80 per share in cash. Illumina is not affiliated or associated in any way with TRC, its offer or the offer documentation. Illumina recommends that stockholders not tender their shares in response to TRC's unsolicited offer because, among other things, it deprives stockholders who tender their Illumina shares of the potential opportunity to realize greater long-term value in their investment.
- Zacks
Illumina Banks on New Product Suite Despite Margin Woes
The unveiling of Veriseq NIPT v2 and Illumina's (ILMN) alliance with AnchorDx in the second quarter further raise investor confidence in the stock.
- Simply Wall St.
With 45% Earnings Growth, Did Illumina, Inc. (NASDAQ:ILMN) Outperform The Industry?
Examining Illumina, Inc.'s (NASDAQ:ILMN) past track record of performance is a useful exercise for investors. It...
- Zacks
Probability 101: How Not to Be a Sucker
We need science and math -- and STEM-savvy minds -- more than ever to help us inform decision making.
- Zacks
Illumina (ILMN) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Illumina (ILMN) closed at $271.71, marking a -0.17% move from the previous day.
- Zacks
ETFs to Gain From the Booming Genomics Market
Rising investments, surging demand for personalized medicines and shrinking sequencing costs are a slew of factors favouring the genomics space. We look at a few ETFs that can cash in on this trend.
